Gain Therapeutics: Funding, Investors & Team (Sep 2026)
Gain Therapeutics is a company that creates pharmacological chaperone drugs for rare metabolic disorders. Their drugs use Minoryx Direct Enzyme Therapy to discover new adjuvants that can help stabilize misfolding mutations and restore enzyme activity in patients. They focus on developing innovative drugs for rare pediatric genetic disorders and CNS diseases with significant medical needs. The company was founded in 2017 and is based in Bethesda, MD, USA.
Gain Therapeutics has raised $7.0M across 1 funding round on record, the most recent an undisclosed round of $7.0M announced in Jul 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Gain Therapeutics Company Profile and Key Stats
Latest funding round on record: Jul 2025.
Gain Therapeutics Funding Rounds
Gain Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Gain Therapeutics Funding Compared to Other Biotechnology Startups
Gain Therapeutics' latest round of $7.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Gain Therapeutics in Biotechnology and Bethesda
Companies Similar to Gain Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Gain Therapeutics Funding FAQs
What does Gain Therapeutics do?
Gain Therapeutics is a company that creates pharmacological chaperone drugs for rare metabolic disorders. Their drugs use Minoryx Direct Enzyme Therapy to discover new adjuvants that can help stabilize misfolding mutations and restore enzyme activity in patients. They focus on developing innovative drugs for rare pediatric genetic disorders and CNS diseases with significant medical needs. The company was founded in 2017 and is based in Bethesda, MD, USA.
How much funding has Gain Therapeutics raised?
Gain Therapeutics has raised $7.0M across 1 round on record. The most recent is an undisclosed round of $7.0M announced in Jul 2025.
When did Gain Therapeutics last raise funding?
Gain Therapeutics' most recent funding round on record is an undisclosed round of $7.0M, announced in Jul 2025.
Who founded Gain Therapeutics?
FundedIQ lists Lorenzo Leoni (Founder) at Gain Therapeutics.
Where is Gain Therapeutics headquartered?
Gain Therapeutics is based in Bethesda, Maryland, United States.
How many employees does Gain Therapeutics have?
Gain Therapeutics is in the 11-50 employee band.
How does Gain Therapeutics' funding compare to other Biotechnology startups?
Gain Therapeutics' latest round of $7.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Gain Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Gain Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.